- Home
- LCFY vs PULM Comparison
LCFY vs PULM Comparison
Compare LCFY & PULM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LCFY | PULM |
|---|---|---|
| Founded | 2009 | 2003 |
| Country | Australia | United States |
| Employees | 18 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.4M | 9.4M |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | LCFY | PULM |
|---|---|---|
| Price | $4.20 | $1.30 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 13.6K | ★ 73.3K |
| Earning Date | 03-13-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 46.18 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,910,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 5069.93 |
| 52 Week Low | $2.50 | $1.20 |
| 52 Week High | $13.98 | $9.37 |
Technical Indicators
Market Signals| Indicator | LCFY | PULM |
|---|---|---|
| Relative Strength Index (RSI) | 50.06 | 29.48 |
| Support Level | $4.07 | N/A |
| Resistance Level | $4.80 | $4.97 |
| Average True Range (ATR) | 0.24 | 0.16 |
| MACD | -0.07 | -0.09 |
| Stochastic Oscillator | 31.37 | 6.25 |
Price Performance
Historical ComparisonAbout LCFY Locafy Limited
Locafy Ltd is an Australian company currently focused on commercializing its Software as a Service (SaaS) online marketing technology (Technology), which prominently delivers a cost-effective location-based digital marketing solution for small businesses in the key markets of the USA, Australia and Canada. The company has two operating segments: Publishing and SEO Agency. The company derives the majority of its revenue from license subscription fees and advertising fees. Geographically, the maximum revenue is derived from North America.
About PULM Pulmatrix Inc.
Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).